- Obesity and Metabolism
- Olanzapine-Induced Diabetic Ketoacidosis and Neuroleptic Malignant Syndrome with Rhabdomyolysis: A Case Report
-
Young Kyoung Sa, Hyeon Yang, Hee Kyoung Jung, Jang Won Son, Seong Su Lee, Seong Rae Kim, Bong Yeon Cha, Ho Young Son, Chi-Un Pae, Soon Jib Yoo
-
Endocrinol Metab. 2013;28(1):70-75. Published online March 25, 2013
-
DOI: https://doi.org/10.3803/EnM.2013.28.1.70
-
-
4,677
View
-
41
Download
-
7
Crossref
-
Abstract
PDFPubReader
Atypical antipsychotics have replaced conventional antipsychotics in the treatment of schizophrenia because they have less of a propensity to cause undesirable neurologic adverse events including extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome (NMS). However, atypical antipsychotics have been known to result in various metabolic complications such as impaired glucose tolerance, diabetes and even diabetic ketoacidosis (DKA). In addition, a number of NMS cases have been reported in patients treated with atypical antipsychotics, although the absolute incidence of neurologic side effects is currently significantly low. Here, we report a patient who simultaneously developed DKA, acute renal failure and NMS with rhabdomyolysis after olanzapine treatment. Olanzapine-induced metabolic complications and NMS were dramatically improved with cessation of the olanzapine treatment and initiation of supportive management including fluid therapy, hemodialysis, and intensive glycemic control using insulin. At short-term follow-up, insulin secretion was markedly recovered as evidenced by a restoration of serum C-peptide level, and the patient no longer required any hypoglycemic medications. Despite the dramatic increase in the use of atypical antipsychotics treatment, individualized treatments along with careful monitoring may be prudent for high risk or vulnerable patients in order to avoid the development of metabolic side effects.
-
Citations
Citations to this article as recorded by
- Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report
Francesco Piacenza, Suet Kee Ong, Patrick O’Brien, Maurice Clancy Clinical Case Reports.2021; 9(4): 2404. CrossRef - Succinylcholine-Induced Rhabdomyolysis in Adults: Case Report and Review of the Literature
Robert William Barrons, Liem T. Nguyen Journal of Pharmacy Practice.2020; 33(1): 102. CrossRef - Improvement in renal prognosis with prompt hemodialysis in hyperosmolar hyperglycemic state-related rhabdomyolysis
I-Wen Chen, Cheng-Wei Lin Medicine.2018; 97(50): e13647. CrossRef - Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication
Antonia Vuk, Maja Baretic, Martina Matovinovic Osvatic, Igor Filipcic, Nikolina Jovanovic, Martina Rojnic Kuzman Journal of Clinical Psychopharmacology.2017; 37(5): 584. CrossRef - A Case of Primary Hypoparathyroidism Presenting with Acute Kidney Injury Secondary to Rhabdomyolysis
Abdullah Sumnu, Zeki Aydin, Meltem Gursu, Sami Uzun, Serhat Karadag, Egemen Cebeci, Savas Ozturk, Rumeyza Kazancioglu Case Reports in Nephrology.2016; 2016: 1. CrossRef - Nanoneurotherapeutics approach intended for direct nose to brain delivery
Shadab Md, Gulam Mustafa, Sanjula Baboota, Javed Ali Drug Development and Industrial Pharmacy.2015; 41(12): 1922. CrossRef - Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee Endocrinology and Metabolism.2014; 29(3): 251. CrossRef
|